Jordan S Taylor1, Jasmine Zeki1, Kimberly Ornell2, Jeannine Coburn2, Hiroyuki Shimada3, Naohiko Ikegaki4, Bill Chiu5. 1. Department of Surgery, Stanford University, Stanford, CA. 2. Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA. 3. Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA. 4. Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL. 5. Department of Surgery, Stanford University, Stanford, CA; Department of Surgery, University of Illinois at Chicago, Chicago, IL. Electronic address: bhsc@stanford.edu.
Abstract
PURPOSE: MYCN oncogene amplification is an independent predictor of poor prognosis in neuroblastoma. CX-5461 is a small molecular inhibitor that prevents initiation of ribosomal RNA (rRNA) synthesis by RNA Pol I, down-regulating MYCN/MYC proteins. We hypothesize that neuroblastoma tumor growth can be suppressed by CX-5461. METHODS: MYCN-amplified (KELLY, IMR5) and nonamplified (SY5Y, SKNAS) neuroblastoma cells were treated with CX-5461. MYCN/MYC expression after 24-48 h was determined by Western blot. Orthotopic neuroblastoma tumors created in mice using KELLY cells were treated with CX-5461-loaded silk films implanted locally. Tumor growth was monitored using ultrasound. Histologic evaluation of tumors was performed. RESULTS: IC50 for KELLY, IMR5, SY5Y, and SKNAS cells to CX-5461 was 0.75 μM, 0.02 μM, 0.8 μM, and 1.7 μM, respectively. CX-5461 down-regulated MYCN and MYC proteins at 0.25-1.0 μM on Western blot analysis. CX-5461-loaded silk film released 23.7±3 μg of the drug in 24 h and 48.2±3.9 μg at 120 h. KELLY tumors treated with CX-5461-loaded film reached 800 mm3 after 7.8±1.4 days, while those treated with control film reached the same size on 5.1±0.6 days (p=0.03). CX-5461-treated tumors showed collapse of nucleolar hypertrophy and MYCN protein downregulation. CONCLUSION: We demonstrated that local delivery of CX-5461 via sustained release platform can suppress orthotopic neuroblastoma tumor growth, especially those with MYCN/MYC overexpression.
PURPOSE:MYCN oncogene amplification is an independent predictor of poor prognosis in neuroblastoma. CX-5461 is a small molecular inhibitor that prevents initiation of ribosomal RNA (rRNA) synthesis by RNA Pol I, down-regulating MYCN/MYC proteins. We hypothesize that neuroblastoma tumor growth can be suppressed by CX-5461. METHODS:MYCN-amplified (KELLY, IMR5) and nonamplified (SY5Y, SKNAS) neuroblastoma cells were treated with CX-5461. MYCN/MYC expression after 24-48 h was determined by Western blot. Orthotopic neuroblastoma tumors created in mice using KELLY cells were treated with CX-5461-loaded silk films implanted locally. Tumor growth was monitored using ultrasound. Histologic evaluation of tumors was performed. RESULTS: IC50 for KELLY, IMR5, SY5Y, and SKNAS cells to CX-5461 was 0.75 μM, 0.02 μM, 0.8 μM, and 1.7 μM, respectively. CX-5461 down-regulated MYCN and MYC proteins at 0.25-1.0 μM on Western blot analysis. CX-5461-loaded silk film released 23.7±3 μg of the drug in 24 h and 48.2±3.9 μg at 120 h. KELLY tumors treated with CX-5461-loaded film reached 800 mm3 after 7.8±1.4 days, while those treated with control film reached the same size on 5.1±0.6 days (p=0.03). CX-5461-treated tumors showed collapse of nucleolar hypertrophy and MYCN protein downregulation. CONCLUSION: We demonstrated that local delivery of CX-5461 via sustained release platform can suppress orthotopic neuroblastomatumor growth, especially those with MYCN/MYC overexpression.
Authors: Carla Grandori; Natividad Gomez-Roman; Zoe A Felton-Edkins; Celine Ngouenet; Denise A Galloway; Robert N Eisenman; Robert J White Journal: Nat Cell Biol Date: 2005-03 Impact factor: 28.824
Authors: Jaime Torres; Paul L Regan; Robby Edo; Payton Leonhardt; Eric I Jeng; Eric F Rappaport; Naohiko Ikegaki; Xao X Tang Journal: Int J Oncol Date: 2010-10 Impact factor: 5.650
Authors: Jung-Hee Kang; Piotr G Rychahou; Titilope A Ishola; Jingbo Qiao; B Mark Evers; Dai H Chung Journal: Biochem Biophys Res Commun Date: 2006-10-12 Impact factor: 3.575
Authors: Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Catherine A Burkhart; Andy J Cheng; Janice Madafiglio; Maria Kavallaris; Mario Mili; Glenn M Marshall; William A Weiss; Levon M Khachigian; Murray D Norris; Michelle Haber Journal: J Natl Cancer Inst Date: 2003-09-17 Impact factor: 13.506
Authors: B De Bernardi; V Mosseri; H Rubie; V Castel; A Foot; R Ladenstein; G Laureys; M Beck-Popovic; A F de Lacerda; A D J Pearson; J De Kraker; P F Ambros; Y de Rycke; M Conte; P Bruzzi; J Michon Journal: Br J Cancer Date: 2008-09-02 Impact factor: 7.640
Authors: Sara Lundsten; Hanna Berglund; Preeti Jha; Cecilia Krona; Mehran Hariri; Sven Nelander; David P Lane; Marika Nestor Journal: Biomolecules Date: 2021-11-15
Authors: Jean-Clément Mars; Michel G Tremblay; Mélissa Valere; Dany S Sibai; Marianne Sabourin-Felix; Frédéric Lessard; Tom Moss Journal: NAR Cancer Date: 2020-11-06